David Zhang, MD

David Zhang, MD, is a pulmonary disease medicine specialist at Columbia University Irving Medical Center.

Articles by David Zhang, MD

Polygenic Risk Scores Move Closer to IPF Clinical Use: David Zhang, MD

July 24th 2026

Polygenic risk scores show promise for idiopathic pulmonary fibrosis (IPF), though clinical implementation challenges remain, said David Zhang, MD.

Challenges to Clinical Implementation of IPF Polygenic Risk Scores: David Zhang, MD

BySabrina McCrear,David Zhang, MD

July 22nd 2026

David Zhang, MD, discusses the limitations of polygenic risk scores and remaining barriers to their clinical use in idiopathic pulmonary fibrosis.

Real-World PRS Data Advance IPF Risk Prediction, Diagnosis: David Zhang, MD

BySabrina McCrear,David Zhang, MD

July 21st 2026

David Zhang, MD, discusses how real-world EHR and biobank data could advance polygenic risk scores for IPF diagnosis and risk prediction.

Polygenic Risk Scores, Telomere Length Shape IPF Risk: David Zhang, MD

BySabrina McCrear,David Zhang, MD

February 16th 2026

A new study links telomere length and polygenic risk scores to IPF development, highlighting genetic drivers beyond rare variants.

David Zhang, MD, explains how telomere biology and genetic endotypes could reshape risk prediction and personalized approaches for idiopathic pulmonary fibrosis.

Telomere Genetics Offer New Clues to IPF Risk: A Q&A With David Zhang, MD

BySabrina McCrear,David Zhang, MD

February 13th 2026

A new study links telomere length genetics to IPF risk, showing how rare variants and polygenic scores may guide future screening and precision care.

David Zhang, MD

Articles by David Zhang, MD

Polygenic Risk Scores Move Closer to IPF Clinical Use: David Zhang, MD

Challenges to Clinical Implementation of IPF Polygenic Risk Scores: David Zhang, MD

Real-World PRS Data Advance IPF Risk Prediction, Diagnosis: David Zhang, MD

Polygenic Risk Scores, Telomere Length Shape IPF Risk: David Zhang, MD

Telomere Genetics Offer New Clues to IPF Risk: A Q&A With David Zhang, MD

Latest Updated Articles

Trending on AJMC

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

Setting Treatment Goals in RA: Remission, Joint Damage, and Systemic Risk

Predicting GLP-1 Discontinuation From Pharmacy Claims

Avoiding TNF Cycling: When to Switch Drug Classes in Rheumatoid Arthritis

Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

David Zhang, MD

Articles by David Zhang, MD

Polygenic Risk Scores Move Closer to IPF Clinical Use: David Zhang, MD

Challenges to Clinical Implementation of IPF Polygenic Risk Scores: David Zhang, MD

Real-World PRS Data Advance IPF Risk Prediction, Diagnosis: David Zhang, MD

Polygenic Risk Scores, Telomere Length Shape IPF Risk: David Zhang, MD

Telomere Genetics Offer New Clues to IPF Risk: A Q&A With David Zhang, MD

Latest Updated Articles

Trending on AJMC

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

Setting Treatment Goals in RA: Remission, Joint Damage, and Systemic Risk

Predicting GLP-1 Discontinuation From Pharmacy Claims

Avoiding TNF Cycling: When to Switch Drug Classes in Rheumatoid Arthritis

Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups